Company
Dianthus
Dianthus Therapeutics
Also known as Dianthus Therapeutics, Dianthus Therapeutics, Inc
- Status
- Mergedas of 2026-09-17Source (opens in a new tab)
- Business model
- B2B
- Customers
- patients living with severe autoimmune diseases
- Legal name
- Dianthus Therapeutics, Inc
Claim, correct or request removal
Record updated 29 September 2026
About
Dianthus Therapeutics (DNTH) is a biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency over existing complement therapies for the treatment of severe and rare autoimmune diseases. Merged into public company in September 2023
Funding snapshot
- Total raised
- $122MSEC form D sum, as of 2026-09-29Source (opens in a new tab)
- Latest round
- Round, $100M2022-04-06
Funding rounds
- Round, 2022
- $100M2022-04-06, SEC form D sold, 22 investors
- Round, 2021
- $15M2021-05-26, SEC form D sold, 6 investors
- Round, 2021
- $7.7K2021-04-19, SEC form D sold, 1 investor
- Round, 2019
- $6.5M2019-07-19, SEC form D sold, 6 investors
About the company
- Status notes
- Merged into public company in September 2023
Products
- Web
- claseprubart (DNTH103)
- Web
- DNTH212
Loading relationship preview